HIVE vs GEMI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 11, 2026

HIVE

57.4
AI Score
VS
HIVE Wins

GEMI

40.7
AI Score

Investment Advisor Scores

HIVE

57score
Recommendation
BUY

GEMI

41score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE GEMI Winner
Forward P/E 62.8931 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth 73.5% 36.6% HIVE
Earnings Growth -99.9% 0.0% GEMI
Tradestie Score 57.4/100 40.7/100 HIVE
Profit Margin -98.5% -250.1% HIVE
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: +10.6% · 3M: -20.1% GEMI 1M: +7.0% · 3M: -3.9%

Current Technical Phase

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.8 · Price: $3.03

GEMI

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.9 · Price: $4.46

Fundamentals Snapshot

Metric HIVE GEMI
Market Cap
Forward P/E -5.9 -2.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.7% 0.4%
Gross Margin 0.4% -0.3%
Operating Margin -0.6% -1.7%
EPS -1.33 -14.81
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.